Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup
Ligand Pharmaceuticals plans to acquire recombinant protein therapeutics maker Pfenex for $438 million, the companies announced Monday. The larger company agreed to pay $12 per share for Pfenex (NYSE American: PFNX)—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: LGND) generates revenue from licensing deals and royalties paid by pharmaceutical companies […]